| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | empagliflozin/metformin (Synjardy®) |
| Formulation | 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg film-coated tablet |
| Reference number | 2131 |
| Indication | Treatment of adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone; in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin; in patients already being treated with the combination of empagliflozin and metformin as separate tablets |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 26/05/2015 |